722 related articles for article (PubMed ID: 21335144)
1. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
[TBL] [Abstract][Full Text] [Related]
3. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Csaky K; Do DV
Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Mitchell P
Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
9. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
10. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF therapy: comparison of current and future agents.
Pieramici DJ; Rabena MD
Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Nguyen CL; Oh LJ; Wong E; Wei J; Chilov M
BMC Ophthalmol; 2018 May; 18(1):130. PubMed ID: 29843663
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
16. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
Kohly RP; Muni RH; Kertes PJ; Lam WC
Can J Ophthalmol; 2011 Feb; 46(1):46-50. PubMed ID: 21283157
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
19. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]